<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02400320</url>
  </required_header>
  <id_info>
    <org_study_id>202201</org_study_id>
    <nct_id>NCT02400320</nct_id>
  </id_info>
  <brief_title>Local Skin Safety Study of a Topical Pain Relief Spray Containing a Combination of Diclofenac, Methyl Salicylate, and Menthol</brief_title>
  <official_title>Cumulative Skin Irritation Study Evaluating the Skin Irritancy Potential of Topical Analgesic Vovilup Spray Containing a Combination of Diclofenac, Menthol, Methyl Salicylate and Linseed Oil and Comparing it With a Marketed Formulation - Iodex Ultragel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine local skin safety of a topical analgesic spray
      containing a combination of diclofenac, methyl salicylate, menthol and compare it with a
      topical analgesic gel containing a combination of diclofenac, methyl salicylate, and menthol.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date type="Anticipated">March 1, 2016</start_date>
  <completion_date type="Anticipated">June 30, 2016</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean cumulative irritation score</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Skin Irritation</condition>
  <arm_group>
    <arm_group_label>Topical Spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical spray containing Diclofenac 1.16%, Linseed Oil 3%, Menthol 5%, Methyl salicylate 10%.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical gel containing Diclofenac 1.16%, Menthol 5%, Methyl salicylate 10%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical Spray</intervention_name>
    <description>Topical spray containing Diclofenac 1.16%, Linseed Oil 3%, Menthol 5%, Methyl salicylate 10%.</description>
    <arm_group_label>Topical Spray</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical Gel</intervention_name>
    <description>Topical gel containing Diclofenac 1.16%, Menthol 5%, Methyl salicylate 10%</description>
    <arm_group_label>Topical Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Saline</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Healthy male or female volunteers aged at least 18 years.

          2. Good general, physical and mental health in the opinion of the investigator or
             medically qualified designee:

               -  No clinically significant and relevant abnormalities in medical history or upon
                  physical examination.

               -  Absence of any condition that could affect the volunteer's safety or well being
                  or their ability to understand and follow study procedures and requirements.

          3. Healthy volunteers who do not have excessive hair on the volar aspect of the
             forearm(s).

          4. Healthy volunteers should understand and be willing to fully comply with all study
             procedures and restrictions.

          5. Demonstrates understanding of the study and willingness to participate as evidenced by
             voluntary written informed consent and has received a signed and dated copy of the
             informed consent form.

          6. Females of childbearing potential, using an effective contraceptive method for at
             least one month before the beginning of the study, and willing to use throughout the
             study

        Exclusion Criteria

          1. Volunteers having recent history (within one year) of alcohol or other substance abuse
             as determined by medical history.

          2. Participation in another clinical study or receipt of an investigational drug within
             30 days of the screening visit.

          3. Previous participation in similar study with similar products.

          4. Volunteer has any visible skin disease at the site of application that, in the opinion
             of the investigator, will interfere with the skin assessments.

          5. Volunteer has current or relevant previous history of serious, severe or unstable
             physical or psychiatric illness, or medical disorders, such as current or previous
             history of hepatic or renal diseases (impairment) or peptic ulcer as determined by
             medical history.

          6. Volunteer has a history of hypersensitivity (e.g. asthma, bronchospasm, rhinitis,
             urticaria, nasal polyps) to aspirin, diclofenac, other non steroidal anti-inflammatory
             drugs (NSAIDs), menthol or any of the excipients in the test product(s).

          7. Volunteer is receiving systemic or topical NSAIDs, other oral or topical analgesics or
             antihistamine within 3 days of visit 1, or other medication (such as corticosteroids
             within 3 weeks of visit 1) which, in the opinion of the investigative personnel, will
             interfere with the study results.

          8. Female volunteers who are pregnant, planning to become pregnant during the study, or
             are breast-feeding.

          9. Female volunteers who have positive pregnancy test.

         10. Volunteers who are employees of the sponsor or study site or an immediate family
             member (e.g. partner, offspring, parents, siblings or sibling's offspring) of such
             employees.

         11. Any skin disorder at the test site that in the investigator's judgement can affect the
             readings of the test result

         12. Any concomitant medications that in the investigator's judgement can confound or alter
             test results or evaluation of adverse events.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2015</study_first_submitted>
  <study_first_submitted_qc>March 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2015</study_first_posted>
  <last_update_submitted>September 11, 2017</last_update_submitted>
  <last_update_submitted_qc>September 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Salicylates</mesh_term>
    <mesh_term>Methyl salicylate</mesh_term>
    <mesh_term>Menthol</mesh_term>
    <mesh_term>Salicylic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

